Print Page | Close Window

Cytokinetics, Inc. (NASDAQ: CYTK) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and other medical conditions.  Cytokinetics currently has three compounds in clinical development: omecamtiv mecarbil in Phase II for acute and chronic heart f Details >>

Link to Annual Report & Stockholder Meeting Materials and Information

Stock Quote
CYTK (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.06 (0.84%)
Market Cap$274,592,500
Shares Outstanding38,675,000
Data as of 03/30/15 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsDetails >>
03/25/15Cytokinetics Announces Publication of Results from Phase II Trial of Tirasemtiv in Patients with Myasthenia GravisPrinter Friendly Version
03/13/15Cytokinetics Announces Completion of Enrollment in COSMIC-HFPrinter Friendly Version
02/27/15Cytokinetics Joins Global Movement to Raise Awareness for Rare DiseasesPrinter Friendly Version
02/26/15Cytokinetics Announces Publication of Preclinical Data Relating to CK-2127107 and Exercise Tolerance in Rodent Model of Heart FailurePrinter Friendly Version
Upcoming EventsDetails >>
05/20/15 10:30 a.m. PT
Cytokinetics, Inc. Annual Shareholder Meeting
LocationEmbassy Suites Hotel
250 Gateway Boulevard
South San Francisco, CA 94080
Featured ReportDetails >>
Download Documentation 2013 Annual Report

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.